Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SDHB | P21912 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3567226 | 0.92 | LOXL2 (0.39) | PTGS2PTGS1PDPK1CA12CA1 | |
| SCHEMBL3564014 | 0.85 | KDM4E (0.42) | PTGS2PTGS1PDPK1CA12CA1 | |
| SCHEMBL3561597 | 0.79 | LOXL2 (0.36) | PTGS2ALDH1A1 | |
| SCHEMBL3564796 | 0.78 | CA12 (0.48) | PTGS2PDPK1CA12CA1CA2 | |
| SCHEMBL3564735 | 0.78 | CA12 (0.37) | PTGS2PDPK1CA12CA1CA2 | |
| SCHEMBL3564433 | 0.77 | KDM4E (0.38) | PTGS2PTGS1PDPK1CA12CA1 | |
| SCHEMBL3571703 | 0.76 | KIF11 (0.37) | PTGS2PTGS1PDPK1ALDH1A1 | |
| SCHEMBL3561944 | 0.74 | CA2 (0.41) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL3560069 | 0.73 | MAPT (0.41) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL3566228 | 0.72 | KDM4E (0.44) | PTGS2PTGS1PDPK1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642264-B2 | Phenyl-substituted pyrimidine derivatives as mGluR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | P2RX2, P2RY2, P2RX1 | PTGS2 693/4885PTGS1 1583/4885PDPK1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.